Evolution and long term outcome in patients presenting with large demyelinating lesions as their first clinical event

2010 ◽  
Vol 297 (1-2) ◽  
pp. 29-35 ◽  
Author(s):  
Pandurang R. Wattamwar ◽  
Neeraj N. Baheti ◽  
Chandrasekharan Kesavadas ◽  
Muralidharan Nair ◽  
Ashalatha Radhakrishnan
Keyword(s):  
Clinical Event ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Demyelinating Lesions

Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis

2016 ◽  
Vol 37 (7) ◽  
pp. 1113-1117 ◽  
Author(s):  
Rocco Totaro ◽  
C. Di Carmine ◽  
A. Splendiani ◽  
S. Torlone ◽  
L. Patriarca ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Demyelinating Lesions

scholarly journals Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Blood ◽  
2010 ◽  
Vol 116 (12) ◽  
pp. 2040-2045 ◽  
Author(s):  
Bertrand Coiffier ◽  
Catherine Thieblemont ◽  
Eric Van Den Neste ◽  
Gérard Lepeu ◽  
Isabelle Plantier ◽  
...  
Keyword(s):  
Randomized Study ◽  
Young Patients ◽  
Progression Free Survival ◽  
B Cell Lymphoma ◽  
Clinical Event ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Risk Of Death ◽  
Event Information

Abstract We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (DLBCL) aged 60 to 80 years, with a median follow-up time of 10 years. Clinical event information was updated in all living patients (with the exception of 3 patients) in 2009. Survival end points were improved in patients treated with R-CHOP: the 10-year progression-free survival was 36.5%, compared with 20% with CHOP alone, and the 10-year overall survival was 43.5% compared with 27.6%. The same risk of death due to other diseases, secondary cancers, and late relapses was observed in both study arms. Relapses occurring after 5 years represented 7% of all disease progressions. The results from the 10-year analysis confirm the benefits and tolerability of the addition of rituximab to CHOP. Our findings underscore the need to treat elderly patients as young patients, with the use of curative chemotherapy.

Long-term outcome of treatment with cyclosporine IV for patients with intractable ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A624-A624 ◽  
Author(s):  
J ARTS ◽  
M ZEEGERS ◽  
G DHAENS ◽  
G VANASSCHE ◽  
M HIELE ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Term Outcome ◽  
Long Term Outcome

1519: Long Term Outcome of Interstitial Laser Coagulation for Benign Prostatic Hyperplasia

2006 ◽  
Vol 175 (4S) ◽  
pp. 490-490
Author(s):  
Stefan Zastrow ◽  
Sven Oehlschläger ◽  
Oliver W. Hakenberg ◽  
Steffen Leike ◽  
Manfred P. Wirth
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Prostatic Hyperplasia ◽  
Laser Coagulation ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Interstitial Laser

1306: Microvascular Arterial Bypass Surgery: Assessment of Long-Term Outcome

2006 ◽  
Vol 175 (4S) ◽  
pp. 420-421
Author(s):  
Gemma Viola Fantini ◽  
Andrew Nisbet ◽  
Pejman Mortarjem ◽  
Claudia Panzer ◽  
Ricardo Munarriz
Keyword(s):  
Bypass Surgery ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Arterial Bypass ◽  
Arterial Bypass Surgery
Sign in / Sign up

Export Citation Format

Share Document